ABCDx and BBI Solutions Successfully Complete Initial Phases of LVOCheck Rapid Test Development


ABCDx and BBI Solutions Successfully Complete Initial Phases of LVOCheck Rapid Test Development; Product Targeted for Mid-2025 Commercial Launch

Geneva, Switzerland — [December 4, 2023] — ABCDx, a pioneer in brain injury diagnostics, and BBI Solutions OEM Limited, a global leader in diagnostic assay development, are thrilled to announce the successful completion of the initial phase of their collaborative development program for the LVOCheck rapid test. The announcement comes as both companies finalize the feasibility phase of the project.

Development Program Overview

The collaboration between ABCDx and BBI has primarily focused on optimizing the assay for the detection of specific markers indicative of brain injuries, including H-FABP, NT-pro BNP, and D-Dimer. The test is designed to work on human whole blood samples and seeks to deliver a quantitative result.

Successful Onboarding and Feasibility Phases

Throughout the Feasibility Phase both companies worked collaboratively, developing comprehensive project plans, selection of critical raw materials, and assessments against ABCDx’s existing devices. This phase also included key milestones such as the selection of biologicals based on assay performance and clinical relevance.

Impact for ABCDx

"As we complete these critical initial phases, we are one step closer to offering a revolutionary product that could change the landscape of brain injury diagnostics," said

Prof. Jean-Charles Sanchez, Co-Founder and CEO of ABCDx. "This accomplishment is not only a technical milestone but also adds significant value to our ongoing Series A fundraising efforts."

“Achieving this technical milestone is testament to the great partnership between ABCDx and BBI. The extensive knowledge and understanding from ABCDx of these brain biomarkers, and the depth of expertise from BBI in applying these biologicals to lateral flow, is the perfect recipe for success” said Mario Gualano, CEO of BBI Solutions.

About ABCDx

Founded and headquartered in Geneva, Switzerland, ABCDx is committed to the democratization of data-driven diagnostics in the field of brain injuries.

About BBI Solutions

BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest independent producer of immuno-diagnostics reagents. Core

competencies include a comprehensive suite of reagents with custom development options, lateral flow development, and diagnostic manufacturing services.

For inquiries, please contact:

Jean-Charles Sanchez


Email :